Latest Conference Articles

The report highlights lebrikizumab’s potential for sustained disease modification and its evolving role in long-term atopic dermatitis management.

Sleep Number studies presented at SLEEP 2025 show that heating and cooling patterns improve sleep quality, especially for women experiencing menopause.

This recap highlights data on stem cell-derived therapies for type 1 diabetes, cortisol-modulating strategies for hard-to-treat type 2 diabetes, and a novel once-weekly insulin alternative that matches daily injections in efficacy.

Read the latest pivotal data on once-monthly injectables, oral GLP-1 agonists, and novel co-agonist therapies from ADA.

Berry discussed findings from a retrospective, real-world study but emphasized that they should be confirmed in randomized controlled trials.

Lifitegrast 5% led to improvements in OSDI, MMP-9, tear osmolarity, and a variety of other biomarkers and clinical signs of DED.

At SLEEP 2025, Levine discussed how skin biopsy testing for phosphorylated alpha-synuclein may enable early diagnosis and prevention trials for neurodegenerative diseases.

At SLEEP 2025, Sachdeva outlined evolving liability concerns, transparency issues, and steps clinicians can take to safely integrate AI in practice.

Explore the urgent need for diabetes specialists and the American College of Diabetology's efforts to enhance care through education and certification.

Hosts sit down for a deep dive into The Diabetes Collective and what it's like operating a diabetes clinic in the modern healthcare landscape.

In this Q&A, Narcisse shared what the association between greater oral microbiome diversity and longer sleep in teens and young adults could mean for early-life disease prevention.

Leading experts discuss managing atopic dermatitis in skin of color in a live recording from the 2025 Revolutionizing Atopic Dermatitis Conference.

Verma went over the STRIDE trial evaluating the GLP-1 RA and its latest findings presented at ADA Scientific Sessions.

Li and Shao discussed the heavy disease burden of type 2 diabetes in the VA population and outlined the VA MOVE! study.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 notable dermatology updates from the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.

At SLEEP 2025, Sachdeva discussed the evolving legal implications of AI use in sleep medicine, including clinician liability, informed consent, and responsible integration into care.

Discover how the CATALYST trial reveals mifepristone's potential to enhance glycemic control and weight loss in challenging type 2 diabetes cases.

Mifepristone shows promise in improving glycemic control and reducing weight in patients with hypercortisolism and type 2 diabetes.

Maridebart cafraglutide shows potential as a monthly treatment for obesity and type 2 diabetes, demonstrating significant weight loss and glycemic improvements.

At SLEEP 2025, HCPLive spoke with Narcisse about NHANES-based findings suggesting longer sleep duration is associated with richer and more diverse oral microbiomes.

Sandforth emphasized the important of achieving prediabetes remission for preventing T2D as seen in his new research.

Explore groundbreaking findings from the REDEFINE trials on CagriSema's impact on weight loss and diabetes management at ADA 2025.

Philis-Tsimikas shared the latest findings demonstrating inferiority after switching from daily basal insulin to weekly insulin efsitora.

Kevin Sayer joins the program to discuss the latest from Dexcom and preview where the business is headed in an evolving diabetes landscape.

A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes.

Steger discussed findings from a 6-month lifestyle investigating TRE+ER and IER.

CagriSema shows weight loss results in recent trials comparable to existing interventions.

Xue discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention.